J Menopausal Med.  2016 Apr;22(1):9-13. 10.6118/jmm.2016.22.1.9.

Flibanserin for Treating Hypoactive Sexual Desire Disorder

• Sang JH
• Kim TH
• Kim SA

• KMID: 2200914
• DOI: http://doi.org/10.6118/jmm.2016.22.1.9

Abstract

There have been several products developed for male sexual dysfunction. However, developing agents for female sexual dysfunction is lagging behind for various reasons. Sildenafil citrate (Viagra) and Tadalafil (Cialis), which have been prescribed for male sexual function disorders, are known to act on vessels.[1] On the other hand, flibanserin is thought to act on brain. Flibanserin has been approved by U. S. Food and Drug Administration (FDA) for treatment of hypoactive sexual desire disorder (HSDD) of premenopausal women in 2015, and is expected to be released in South Korea soon. Authors wrote this article to acknowledge flibanserin to sexologists for females or physicians for menopausal medicine, so that this agent can be safely used for females who have HSDD.

Keyword

Flibanserin; Sexual behavior; Sexual dysfunctions, psychological; Sildenafil citrate

MeSH Terms

Brain
Citric Acid
Female
Hand
Humans
Korea
Male
Sexual Behavior
Sexual Dysfunctions, Psychological*
United States Food and Drug Administration
Sildenafil Citrate
Tadalafil
Citric Acid

Reference

1. Kim MJ, Kim TH, Lee HH. G-protein coupled estrogen receptor (GPER/GPR30) and womens health. J Menopausal Med. 2015; 21:79–81.

2. Kang BM. Menopausal symptoms and comwplementary and alternative therapy. J Korean Soc Menopause. 2007; 13:164–172.

3. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S. Pharmacology of flibanserin. CNS Drug Rev. 2002; 8:117–142.

4. Kennedy S. Flibanserin: initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder. J Sex Med. 2010; 7:3449–3459.

5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association;2000.

6. Derogatis LR, Komer L, Katz M, Moreau M, Kimura T, Garcia M Jr, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET study. J Sex Med. 2012; 9:1074–1085.

7. Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M Jr, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med. 2012; 9:793–804.

8. Katz M, DeRogatis LR, Ackerman R, Hedges P, Lesko L, Garcia M Jr, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med. 2013; 10:1807–1815.

9. U. S. Food and Drug Administration. FDA briefing document: Joint meeting of the bone, reproductive and urologic drugs advisory committee (BRUDAC) and the drug safety and risk management (DSaRM) advisory committee. Silver Spring, MD: U. S. Food and Drug Administration;2015. cited by 2015 June 29. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM449088.pdf.

10. Pollack A. 'Viagra for Women' gets push for F.D.A. approval. New York, NY: The New York Times Company;2015. cited by 2015 June 24. Available from: http://www.nytimes.com/2015/06/01/business/groups-press-fda-toapprove-womens-viagra.html?_r=2#.

11. Taverinise S, Pollack A. Aid to women, or bottom line? Advocates split on libido pill. New York, NY: The New York Times Company;2015. cited by 2015 June 24. Available from: http://www.nytimes.com/2015/06/14/us/aid-towomen-or-bottom-line-advocates-split-on-libido-pill.html#.

12. Gnanasakthy A, Mordin M, Clark M, DeMuro C, Fehnel S, Copley-Merriman C. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health. 2012; 15:437–442.

13. Derogatis L, Clayton A, Lewis-D'Agostino D, Wunderlich G, Fu Y. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med. 2008; 5:357–364.

14. Kwak EK, Park HS, Kang NM. Menopause knowledge, attitude, symptom and management among midlife employed women. J Menopausal Med. 2014; 20:118–125.

15. Kim HK, Kang SY, Chung YJ, Kim JH, Kim MR. The recent review of the genitourinary syndrome of menopause. J Menopausal Med. 2015; 21:65–71.

16. Kim S, Park HT, Lee BI, Shin JH, Park HM, Kim T. Comparison of the efficacy and safety of the unicenta and melsmon injection for the menopausal symptoms. J Korean Soc Menopause. 2013; 19:36–44.